Company

Huadong Medicine's Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent
Clinical trial resultsHuadong Medicine

Huadong Medicine’s Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent

Huadong Medicine Co., Ltd. (SHE: 000963) announced positive topline results from its Phase III clinical study (HDM1002‑301) evaluating HDM1002 tablets (Conveglipron Trometamol Tablets), a Class 1 oral small‑molecule GLP‑1 receptor…

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
Market launchOTCMKTS: RHHBY

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
HIV / AIDS careMerck

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

CancerEPA: IPN

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Cereblink TechnologyInnovative Medical Management

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Show More